An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS)

Decitabine 20 mg per m\^2 will be administered intravenous infusion over 1 hour, once daily for 5 consecutive days of a 28 days cycle up to 8 cycles or continued until disease progression or unacceptable toxicity.